other material
confidence high
sentiment positive
materiality 0.90
Viridian Therapeutics announces positive phase 3 topline results for elegrobart in active thyroid eye disease
Viridian Therapeutics, Inc.\DE
- REVEAL-1 met primary endpoint with 54% proptosis responder rate for elegrobart Q4W vs 18% placebo at week 24 (p<0.0001).
- Elegrobart Q8W achieved 63% proptosis responder rate vs 18% placebo at week 24.
- Complete resolution of diplopia in 51% of Q4W patients vs 16% placebo at week 24.
- BLA submission for elegrobart anticipated in Q1 2027; REVEAL-2 top-line data expected Q2 2026.
- Company ended Q4 2025 with $875M cash; veligrotug PDUFA date June 30, 2026.